(Q37806321)

23 August 2017

title

Treatment of diabetic retinopathy with anti-VEGF drugs (English)

1 reference

23 August 2017

1 reference

3

Anat Loewenstein

1 reference

23 August 2017

Michael Waisbourd

1

1 reference

23 August 2017

Michaella Goldstein

series ordinal

2

1 reference

23 August 2017

language of work or name

1 reference

2 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

89

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

203-207

1 reference

Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

21 January 2018

Retinopathy in diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

INTRAVITREAL BEVACIZUMAB AND PANRETINAL PHOTOCOAGULATION FOR PROLIFERATIVE DIABETIC RETINOPATHY ASSOCIATED WITH VITREOUS HEMORRHAGE

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.02010.X

10.1111/J.1755-3768.2010.02010.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference